Overview

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Status:
Recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

Phase:

Phase 1

Details

Lead Sponsor:

University of Rochester

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Pembrolizumab
Pemetrexed